Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	5.3	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Breast				
Male	1	0.2	nc	(nc-nc)
Female	23	21.1	109.1	(69.1-163.7)
Cervix Uteri				
Female	1	0.8	nc	(nc-nc)
Colon / Rectum				
Male	8	6.5	123.7	(53.3-243.8)
Female	3	4.8	nc	(nc-nc)
Esophagus				
Male	0	1.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	3.3	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Larynx				
Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	2	2.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	5	10.3	48.5	(15.6-113.2)
Female	4	8.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	7	3.8	185.6	(74.3-382.4)
Female	5	2.6	192.3	(62-448.7)
Multiple Myeloma				
Male	2	1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	3.2	nc	(nc-nc)
Female	5	2.2	230.9	(74.4-538.9)
Oral Cavity & Pharynx				
Male	1	2.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Ovary				
Female	2	1.8	nc	(nc-nc)
Pancreas				
Male	3	1.8	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)
Prostate				
Male	32	24.4	131.3	(89.8-185.4)
Stomach				
Male	2	1.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Testis				
Male	1	0.6	nc	(nc-nc)
Thyroid				
Male	3	1.5	nc	(nc-nc)
Female	7	4	174.4	(69.9-359.4)
Uteri Corpus and Uterus, NOS				
Female	6	5	120.3	(43.9-261.9)
All Sites / Types				
Male	80	79.8	100.3	(79.5-124.8)
Female	68	65.1	104.4	(81.1-132.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	16	13.9	114.9	(65.6-186.6)
Female	8	4.7	169.9	(73.2-334.8)
Brain and Other Nervous System				
Male	2	2.6	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)
Breast				
Male	1	0.4	nc	(nc-nc)
Female	48	50.8	94.4	(69.6-125.2)
Cervix Uteri				
Female	0	1.8	nc	(nc-nc)
Colon / Rectum				
Male	12	15.5	77.3	(39.9-135.1)
Female	13	14.7	88.3	(47-151.1)
Esophagus				
Male	6	3.7	162.2	(59.2-353)
Female	0	1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	7.3	109.9	(47.3-216.5)
Female	6	4.1	146.9	(53.6-319.7)
Larynx				
Male	2	2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	7	5.3	132.2	(53-272.5)
Female	5	3.7	135.9	(43.8-317.2)
Liver and Intrahepatic Bile Ducts				
Male	2	4.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Lung and Bronchus				
Male	31	25.4	122	(82.9-173.2)
Female	31	25.1	123.6	(84-175.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	8.9	112.1	(53.7-206.3)
Female	11	6.7	163.4	(81.4-292.3)
Multiple Myeloma				
Male	1	2.5	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	7.9	101.9	(43.9-200.7)
Female	14	6.2	226.4	(123.7-379.9)
Oral Cavity & Pharynx				
Male	4	5.8	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Ovary				
Female	6	4.6	130.9	(47.8-284.9)
Pancreas				
Male	4	4.5	nc	(nc-nc)
Female	5	4.5	110.6	(35.6-258)
Prostate				
Male	56	51.1	109.5	(82.7-142.2)
Stomach				
Male	2	3.3	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)
Testis				
Male	5	1.6	314	(101.2-732.9)
Thyroid				
Male	2	3.1	nc	(nc-nc)
Female	8	9.3	86.1	(37.1-169.7)
Uteri Corpus and Uterus, NOS				
Female	15	11.7	127.9	(71.5-210.9)
All Sites / Types				
Male	194	184.3	105.2	(91-121.1)
Female	199	173.5	114.7	(99.3-131.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	1.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	15	5.9	255.4	(142.8-421.2)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	2	1.9	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Esophagus				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	1	3.1	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.8	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Ovary				
Female	0	0.5	nc	(nc-nc)
Pancreas				
Male	2	0.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Prostate				
Male	3	6.7	nc	(nc-nc)
Stomach				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	1.4	nc	(nc-nc)
All Sites / Types				
Male	18	22.8	79.1	(46.8-125)
Female	25	19.6	127.9	(82.7-188.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	11.2	107.6	(55.5-187.9)
Female	6	3.9	155.8	(56.9-339.1)
Brain and Other Nervous System				
Male	3	2.5	nc	(nc-nc)
Female	2	2	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	60	46.3	129.5	(98.8-166.7)
Cervix Uteri				
Female	3	1.9	nc	(nc-nc)
Colon / Rectum				
Male	16	13.6	117.8	(67.3-191.3)
Female	9	12.9	70	(31.9-132.8)
Esophagus				
Male	3	3.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.1	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	6.6	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)
Larynx				
Male	1	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Leukemia				
Male	4	4.7	nc	(nc-nc)
Female	2	3.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	3.9	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Lung and Bronchus				
Male	20	20.3	98.6	(60.2-152.3)
Female	26	19.3	134.9	(88.1-197.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	7.8	63.8	(20.5-148.8)
Female	4	6.4	nc	(nc-nc)
Multiple Myeloma				
Male	3	2.1	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	7	114.8	(49.4-226.2)
Female	3	5.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	5.5	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)
Ovary				
Female	6	4.1	146.6	(53.5-319)
Pancreas				
Male	3	3.8	nc	(nc-nc)
Female	5	3.7	134.4	(43.3-313.7)
Prostate				
Male	30	43.8	68.5	(46.2-97.8)
Stomach				
Male	2	2.8	nc	(nc-nc)
Female	0	1.6	nc	(nc-nc)
Testis				
Male	2	1.9	nc	(nc-nc)
Thyroid				
Male	2	3.2	nc	(nc-nc)
Female	12	9.9	121.7	(62.8-212.6)
Uteri Corpus and Uterus, NOS				
Female	11	10.1	108.8	(54.2-194.7)
All Sites / Types				
Male	145	158.9	91.3	(77-107.4)
Female	179	152.8	117.1	(100.6-135.6)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	17	16.9	100.5	(58.5-161)
Female	12	5.7	208.7	(107.7-364.6)
Brain and Other Nervous System				
Male	4	2.2	nc	(nc-nc)
Female	3	1.9	nc	(nc-nc)
Breast				
Male	0	0.5	nc	(nc-nc)
Female	68	46.5	146.3	(113.6-185.5)
Cervix Uteri				
Female	4	1.3	nc	(nc-nc)
Colon / Rectum				
Male	17	17.1	99.6	(58-159.5)
Female	14	17.4	80.4	(43.9-134.9)
Esophagus				
Male	2	4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	6.8	87.6	(32-190.7)
Female	7	4.1	169.8	(68-349.9)
Larynx				
Male	0	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Leukemia				
Male	5	5.6	88.9	(28.6-207.4)
Female	2	3.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	4.1	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Lung and Bronchus				
Male	23	29.3	78.5	(49.7-117.8)
Female	25	28.4	88.2	(57-130.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	22	9.2	240.3	(150.5-363.8)
Female	13	6	215.2	(114.5-368)
Multiple Myeloma				
Male	1	2.8	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	8.1	73.8	(27-160.7)
Female	8	6.7	119.3	(51.3-235)
Oral Cavity & Pharynx				
Male	8	5.3	151.6	(65.3-298.7)
Female	1	2.5	nc	(nc-nc)
Ovary				
Female	3	4.5	nc	(nc-nc)
Pancreas				
Male	6	5.3	114	(41.6-248.2)
Female	5	5.6	88.6	(28.5-206.7)
Prostate				
Male	61	51.8	117.7	(90.1-151.3)
Stomach				
Male	3	3.7	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Testis				
Male	1	0.7	nc	(nc-nc)
Thyroid				
Male	4	2.4	nc	(nc-nc)
Female	1	6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	8	10.9	73.3	(31.5-144.4)
All Sites / Types				
Male	204	194.4	105	(91.1-120.4)
Female	200	175.1	114.2	(99-131.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	37	37.8	97.9	(68.9-134.9)
Female	21	14.3	146.9	(90.9-224.5)
Brain and Other Nervous System				
Male	9	7.5	120.7	(55.1-229.2)
Female	6	6.3	95.6	(34.9-208)
Breast				
Male	0	1.2	nc	(nc-nc)
Female	178	154.7	115.1	(98.8-133.3)
Cervix Uteri				
Female	5	5.5	91.3	(29.4-213)
Colon / Rectum				
Male	47	43.3	108.5	(79.7-144.3)
Female	41	45	91.1	(65.4-123.6)
Esophagus				
Male	9	10.5	86	(39.2-163.2)
Female	5	2.9	172.3	(55.5-402.1)
Hodgkin Lymphoma				
Male	3	3	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	20	21	95.4	(58.3-147.4)
Female	9	12.3	73.1	(33.4-138.9)
Larynx				
Male	5	5.8	86.7	(27.9-202.3)
Female	4	1.8	nc	(nc-nc)
Leukemia				
Male	20	14.7	135.9	(83-209.9)
Female	25	11.1	224.5	(145.2-331.4)
Liver and Intrahepatic Bile Ducts				
Male	14	12.3	114	(62.3-191.3)
Female	2	4.2	nc	(nc-nc)
Lung and Bronchus				
Male	72	70	102.9	(80.5-129.6)
Female	66	74.4	88.7	(68.6-112.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	22	25.1	87.6	(54.9-132.6)
Female	22	20.4	107.9	(67.6-163.4)
Multiple Myeloma				
Male	10	7	143.8	(68.8-264.5)
Female	5	5.8	86.2	(27.8-201.1)
Non-Hodgkin Lymphoma				
Male	21	22	95.6	(59.2-146.2)
Female	19	18.7	101.4	(61-158.3)
Oral Cavity & Pharynx				
Male	25	17	146.8	(95-216.7)
Female	7	7.5	93.2	(37.3-191.9)
Ovary				
Female	13	13.9	93.2	(49.6-159.4)
Pancreas				
Male	12	12.6	95.4	(49.3-166.7)
Female	15	13.8	109	(61-179.8)
Prostate				
Male	125	147.8	84.6	(70.4-100.8)
Stomach				
Male	6	9.1	66.2	(24.2-144)
Female	5	5.5	91	(29.3-212.3)
Testis				
Male	5	4.7	106.4	(34.3-248.2)
Thyroid				
Male	13	9.3	140.3	(74.6-239.9)
Female	36	28.2	127.7	(89.4-176.7)
Uteri Corpus and Uterus, NOS				
Female	41	35.7	114.8	(82.3-155.7)
All Sites / Types				
Male	519	519.9	99.8	(91.4-108.8)
Female	575	525.5	109.4	(100.6-118.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	24	26.8	89.4	(57.3-133)
Female	5	9.4	53.2	(17.1-124.2)
Brain and Other Nervous System				
Male	8	6.3	127	(54.7-250.3)
Female	0	5	nc	(nc-nc)
Breast				
Male	0	0.8	nc	(nc-nc)
Female	83	102.3	81.1	(64.6-100.6)
Cervix Uteri				
Female	9	4.4	206.1	(94-391.3)
Colon / Rectum				
Male	32	31.2	102.7	(70.3-145)
Female	31	30.4	102	(69.3-144.8)
Esophagus				
Male	5	7.1	70.1	(22.6-163.7)
Female	1	1.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	3.2	nc	(nc-nc)
Female	1	2.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	14	15	93	(50.8-156.1)
Female	11	8.2	134.5	(67-240.6)
Larynx				
Male	5	3.9	128.2	(41.3-299.1)
Female	0	1.2	nc	(nc-nc)
Leukemia				
Male	12	11.6	103.5	(53.4-180.9)
Female	7	8.4	82.9	(33.2-170.8)
Liver and Intrahepatic Bile Ducts				
Male	14	8.4	167	(91.2-280.2)
Female	4	2.8	nc	(nc-nc)
Lung and Bronchus				
Male	76	48.2	157.6	(124.2-197.3)
Female	55	47.3	116.4	(87.7-151.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	7	18.7	37.5	(15-77.3)
Female	5	15.3	32.8	(10.6-76.5)
Multiple Myeloma				
Male	4	4.9	nc	(nc-nc)
Female	7	3.8	186.5	(74.7-384.3)
Non-Hodgkin Lymphoma				
Male	17	16.6	102.3	(59.6-163.8)
Female	13	12.8	101.7	(54.1-173.9)
Oral Cavity & Pharynx				
Male	7	11.9	58.8	(23.5-121.1)
Female	5	5	99.4	(32-231.9)
Ovary				
Female	3	9.4	nc	(nc-nc)
Pancreas				
Male	8	8.8	90.6	(39-178.5)
Female	14	9.1	153.5	(83.8-257.5)
Prostate				
Male	64	97.3	65.8	(50.7-84)
Stomach				
Male	12	6.5	185.1	(95.5-323.4)
Female	3	3.7	nc	(nc-nc)
Testis				
Male	3	6.2	nc	(nc-nc)
Thyroid				
Male	8	7.6	105.6	(45.5-208.1)
Female	35	23.6	148.6	(103.5-206.7)
Uteri Corpus and Uterus, NOS				
Female	14	22.5	62.1	(33.9-104.2)
All Sites / Types				
Male	351	370.3	94.8	(85.1-105.2)
Female	338	357.3	94.6	(84.8-105.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	6	4.5	134.8	(49.2-293.3)
Female	3	1.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.8	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	10	14.9	67.3	(32.2-123.8)
Cervix Uteri				
Female	0	0.5	nc	(nc-nc)
Colon / Rectum				
Male	5	5.1	98.5	(31.8-230)
Female	2	4.1	nc	(nc-nc)
Esophagus				
Male	2	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	2.4	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Larynx				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	0	1.7	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Lung and Bronchus				
Male	12	8.3	144.6	(74.6-252.6)
Female	1	7	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	2.9	274.4	(118.2-540.8)
Female	1	1.9	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	2.5	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Ovary				
Female	4	1.3	nc	(nc-nc)
Pancreas				
Male	0	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Prostate				
Male	27	17.8	151.3	(99.7-220.1)
Stomach				
Male	0	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Testis				
Male	0	0.5	nc	(nc-nc)
Thyroid				
Male	1	1	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	7	3.5	201.1	(80.6-414.3)
All Sites / Types				
Male	79	61.2	129	(102.2-160.8)
Female	39	49.6	78.6	(55.9-107.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	1.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0	nc	(nc-nc)
Female	6	5.5	108.9	(39.8-237)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	1	1.8	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Esophagus				
Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	4	2.9	nc	(nc-nc)
Female	4	2.5	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	0.7	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Ovary				
Female	2	0.5	nc	(nc-nc)
Pancreas				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Prostate				
Male	8	6.3	127.5	(54.9-251.3)
Stomach				
Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	0	1.3	nc	(nc-nc)
All Sites / Types				
Male	23	21.9	105.1	(66.6-157.7)
Female	15	18.1	82.9	(46.3-136.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0	nc	(nc-nc)
Female	3	5.4	nc	(nc-nc)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	0	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Esophagus				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	2	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	4	2.6	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	0.8	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Ovary				
Female	1	0.5	nc	(nc-nc)
Pancreas				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Prostate				
Male	5	6	83	(26.7-193.7)
Stomach				
Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.4	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	1.3	nc	(nc-nc)
All Sites / Types				
Male	14	20.3	68.8	(37.6-115.5)
Female	13	17.3	75.1	(40-128.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	62	65.9	94.1	(72.1-120.6)
Female	15	25.5	58.9	(32.9-97.1)
Brain and Other Nervous System				
Male	12	12	99.9	(51.6-174.5)
Female	15	10.6	141.8	(79.3-233.9)
Breast				
Male	2	2	nc	(nc-nc)
Female	235	249.7	94.1	(82.5-106.9)
Cervix Uteri				
Female	10	8.5	117	(56-215.1)
Colon / Rectum				
Male	72	72.8	98.8	(77.3-124.5)
Female	81	79.5	101.8	(80.9-126.6)
Esophagus				
Male	18	17.2	104.4	(61.9-165.1)
Female	4	5.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	6	5	120.1	(43.9-261.5)
Female	3	4.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	32	33.5	95.6	(65.4-134.9)
Female	24	20.6	116.2	(74.4-172.9)
Larynx				
Male	8	9.4	85.2	(36.7-167.9)
Female	4	3	nc	(nc-nc)
Leukemia				
Male	22	25	88.2	(55.2-133.5)
Female	13	19.4	67	(35.7-114.6)
Liver and Intrahepatic Bile Ducts				
Male	13	19.7	65.9	(35-112.6)
Female	8	7.3	109.3	(47.1-215.4)
Lung and Bronchus				
Male	148	118.9	124.4	(105.2-146.2)
Female	151	130.1	116.1	(98.3-136.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	20	41.6	48	(29.3-74.2)
Female	19	34.1	55.8	(33.6-87.1)
Multiple Myeloma				
Male	14	11.6	120.3	(65.7-201.8)
Female	9	10.1	88.7	(40.5-168.4)
Non-Hodgkin Lymphoma				
Male	35	36.7	95.3	(66.4-132.5)
Female	29	32.3	89.7	(60-128.8)
Oral Cavity & Pharynx				
Male	26	26.9	96.8	(63.2-141.8)
Female	21	12.6	166.5	(103.1-254.6)
Ovary				
Female	27	23.1	116.7	(76.9-169.9)
Pancreas				
Male	23	21.4	107.4	(68-161.1)
Female	27	24.7	109.1	(71.9-158.8)
Prostate				
Male	178	236.7	75.2	(64.6-87.1)
Stomach				
Male	17	15.4	110.7	(64.5-177.3)
Female	17	9.8	173.2	(100.8-277.3)
Testis				
Male	8	8	100.6	(43.3-198.2)
Thyroid				
Male	5	14.4	34.7	(11.2-80.9)
Female	27	44.5	60.7	(40-88.3)
Uteri Corpus and Uterus, NOS				
Female	52	57.5	90.4	(67.5-118.6)
All Sites / Types				
Male	778	860.7	90.4	(84.2-97)
Female	863	884.9	97.5	(91.1-104.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	5	5	100.6	(32.4-234.8)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	6	1.9	317.1	(115.8-690.2)
Female	3	1.5	nc	(nc-nc)
Esophagus				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.8	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	2	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	2	3.1	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Ovary				
Female	0	0.5	nc	(nc-nc)
Pancreas				
Male	0	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Prostate				
Male	13	6.2	209.3	(111.3-357.9)
Stomach				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	1	0.1	nc	(nc-nc)
Thyroid				
Male	1	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	0	1.2	nc	(nc-nc)
All Sites / Types				
Male	31	22	140.7	(95.5-199.7)
Female	15	17	88.4	(49.4-145.8)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	2.3	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	1	7.9	nc	(nc-nc)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	4	2.6	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)
Esophagus				
Male	2	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.2	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Larynx				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	1	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	6	4.4	137.4	(50.2-299.1)
Female	3	3.9	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.5	nc	(nc-nc)
Female	1	1	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	1.3	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	1	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Ovary				
Female	0	0.7	nc	(nc-nc)
Pancreas				
Male	0	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Prostate				
Male	7	9.2	76.3	(30.6-157.3)
Stomach				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.5	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.9	nc	(nc-nc)
All Sites / Types				
Male	29	31.5	92	(61.6-132.1)
Female	17	26.9	63.3	(36.8-101.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	11	14	78.6	(39.2-140.7)
Female	3	5.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	2.8	nc	(nc-nc)
Female	4	2.4	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	59	57.7	102.3	(77.9-132)
Cervix Uteri				
Female	1	2.1	nc	(nc-nc)
Colon / Rectum				
Male	17	16	106	(61.7-169.8)
Female	17	17.6	96.5	(56.2-154.5)
Esophagus				
Male	3	3.8	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.3	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	7.7	nc	(nc-nc)
Female	7	4.6	151	(60.5-311.1)
Larynx				
Male	3	2.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Leukemia				
Male	4	5.6	nc	(nc-nc)
Female	4	4.4	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	4.5	nc	(nc-nc)
Female	3	1.6	nc	(nc-nc)
Lung and Bronchus				
Male	30	25.5	117.7	(79.4-168)
Female	35	28.1	124.4	(86.7-173.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	9.3	64.3	(23.5-139.9)
Female	4	7.9	nc	(nc-nc)
Multiple Myeloma				
Male	1	2.5	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	3	8.2	nc	(nc-nc)
Female	7	7.2	97.2	(38.9-200.2)
Oral Cavity & Pharynx				
Male	5	6.2	80.6	(26-188.1)
Female	2	2.8	nc	(nc-nc)
Ovary				
Female	0	5.3	nc	(nc-nc)
Pancreas				
Male	3	4.6	nc	(nc-nc)
Female	8	5.4	149.3	(64.3-294.2)
Prostate				
Male	49	52.4	93.5	(69.2-123.6)
Stomach				
Male	5	3.3	149.5	(48.2-348.9)
Female	2	2.2	nc	(nc-nc)
Testis				
Male	0	2.1	nc	(nc-nc)
Thyroid				
Male	2	3.5	nc	(nc-nc)
Female	8	11.1	72	(31-141.9)
Uteri Corpus and Uterus, NOS				
Female	15	13	115.1	(64.3-189.8)
All Sites / Types				
Male	165	190.5	86.6	(73.9-100.9)
Female	193	200.1	96.4	(83.3-111)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	4	9.1	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	1.7	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	33	34.5	95.7	(65.9-134.4)
Cervix Uteri				
Female	0	1.2	nc	(nc-nc)
Colon / Rectum				
Male	16	10.3	155.1	(88.6-252)
Female	8	10.3	77.6	(33.4-152.9)
Esophagus				
Male	1	2.5	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	0.6	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	4.9	nc	(nc-nc)
Female	7	2.7	254.6	(102-524.6)
Larynx				
Male	1	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Leukemia				
Male	2	3.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	2.9	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Lung and Bronchus				
Male	9	16.7	54.1	(24.7-102.6)
Female	13	16.7	77.6	(41.3-132.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	5.8	171	(81.9-314.5)
Female	10	4.4	224.8	(107.6-413.4)
Multiple Myeloma				
Male	2	1.6	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	5.1	nc	(nc-nc)
Female	1	4.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	4	nc	(nc-nc)
Female	3	1.7	nc	(nc-nc)
Ovary				
Female	4	3.1	nc	(nc-nc)
Pancreas				
Male	2	3	nc	(nc-nc)
Female	1	3.1	nc	(nc-nc)
Prostate				
Male	32	34.4	93	(63.6-131.3)
Stomach				
Male	0	2.2	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Testis				
Male	2	0.9	nc	(nc-nc)
Thyroid				
Male	3	2.1	nc	(nc-nc)
Female	7	5.9	117.7	(47.2-242.5)
Uteri Corpus and Uterus, NOS				
Female	6	7.9	76.3	(27.9-166)
All Sites / Types				
Male	108	122	88.5	(72.6-106.9)
Female	119	117.4	101.3	(83.9-121.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	2.3	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	10	7.3	136.9	(65.5-251.8)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	2	2.6	nc	(nc-nc)
Female	2	2	nc	(nc-nc)
Esophagus				
Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Larynx				
Male	1	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	1	0.9	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	4	4.2	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	1.5	nc	(nc-nc)
Female	1	1	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	1.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Ovary				
Female	1	0.7	nc	(nc-nc)
Pancreas				
Male	0	0.8	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Prostate				
Male	5	8.9	56.4	(18.2-131.6)
Stomach				
Male	2	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	0	0.3	nc	(nc-nc)
Thyroid				
Male	0	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	1.7	nc	(nc-nc)
All Sites / Types				
Male	22	31.1	70.8	(44.4-107.3)
Female	26	24.1	107.9	(70.4-158.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	25	25.1	99.7	(64.5-147.2)
Female	6	8.7	69	(25.2-150.2)
Brain and Other Nervous System				
Male	3	4.4	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)
Breast				
Male	1	0.8	nc	(nc-nc)
Female	92	85.3	107.8	(86.9-132.2)
Cervix Uteri				
Female	2	2.7	nc	(nc-nc)
Colon / Rectum				
Male	25	27.9	89.5	(57.9-132.1)
Female	28	27.4	102.2	(67.9-147.8)
Esophagus				
Male	3	6.5	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	15	12.6	118.9	(66.5-196.1)
Female	7	6.9	101.1	(40.5-208.2)
Larynx				
Male	0	3.5	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Leukemia				
Male	11	9.3	118.1	(58.9-211.4)
Female	4	6.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	4	7.5	nc	(nc-nc)
Female	5	2.5	201.3	(64.9-469.8)
Lung and Bronchus				
Male	18	44.8	40.1	(23.8-63.4)
Female	25	43.2	57.8	(37.4-85.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	34	15.6	217.5	(150.6-304)
Female	14	11	127.4	(69.6-213.7)
Multiple Myeloma				
Male	1	4.4	nc	(nc-nc)
Female	3	3.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	13.8	72.4	(34.7-133.1)
Female	9	10.9	82.7	(37.8-157.1)
Oral Cavity & Pharynx				
Male	8	10.2	78.6	(33.8-154.8)
Female	1	4.3	nc	(nc-nc)
Ovary				
Female	9	7.8	114.9	(52.4-218.1)
Pancreas				
Male	8	8.1	98.2	(42.3-193.6)
Female	7	8.4	82.9	(33.2-170.7)
Prostate				
Male	99	88.7	111.6	(90.7-135.8)
Stomach				
Male	1	5.9	nc	(nc-nc)
Female	0	3.4	nc	(nc-nc)
Testis				
Male	3	2.5	nc	(nc-nc)
Thyroid				
Male	4	5.3	nc	(nc-nc)
Female	10	13.6	73.3	(35.1-134.8)
Uteri Corpus and Uterus, NOS				
Female	24	19.6	122.2	(78.3-181.9)
All Sites / Types				
Male	295	323.8	91.1	(81-102.1)
Female	276	297.7	92.7	(82.1-104.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	9	8.5	106.2	(48.5-201.6)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	3	2.5	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)
Esophagus				
Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Larynx				
Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	2	4	nc	(nc-nc)
Female	0	3.5	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	1.5	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Multiple Myeloma				
Male	3	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	1.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Ovary				
Female	3	0.7	nc	(nc-nc)
Pancreas				
Male	1	0.7	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Prostate				
Male	11	9.4	117.2	(58.4-209.7)
Stomach				
Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Testis				
Male	1	0.3	nc	(nc-nc)
Thyroid				
Male	0	0.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	2	nc	(nc-nc)
All Sites / Types				
Male	34	31.1	109.3	(75.7-152.8)
Female	24	26.8	89.4	(57.3-133.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Breast				
Male	0	0	nc	(nc-nc)
Female	7	4.1	170	(68.1-350.2)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	2	1.3	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Esophagus				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.1	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)
Leukemia				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	1	2.1	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)
Female	1	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.7	nc	(nc-nc)
Female	2	0.5	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Ovary				
Female	0	0.4	nc	(nc-nc)
Pancreas				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Prostate				
Male	1	4.5	nc	(nc-nc)
Stomach				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.3	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	4	1	nc	(nc-nc)
All Sites / Types				
Male	9	15.6	57.6	(26.3-109.3)
Female	21	13.7	153.7	(95.1-234.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	8	8.7	92.1	(39.7-181.5)
Female	4	3.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.5	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	30	32.9	91.2	(61.5-130.3)
Cervix Uteri				
Female	3	1.1	nc	(nc-nc)
Colon / Rectum				
Male	15	9.6	155.7	(87.1-256.7)
Female	14	10.5	133.6	(73-224.2)
Esophagus				
Male	3	2.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	4.4	nc	(nc-nc)
Female	0	2.7	nc	(nc-nc)
Larynx				
Male	0	1.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Leukemia				
Male	1	3.3	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	2.6	nc	(nc-nc)
Female	1	1	nc	(nc-nc)
Lung and Bronchus				
Male	14	15.7	89.3	(48.8-149.8)
Female	19	16.9	112.6	(67.8-175.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	12	5.4	220.6	(113.9-385.4)
Female	3	4.4	nc	(nc-nc)
Multiple Myeloma				
Male	2	1.5	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	4.8	104.1	(33.5-242.9)
Female	4	4.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	3.6	nc	(nc-nc)
Female	2	1.6	nc	(nc-nc)
Ovary				
Female	5	3	165.4	(53.3-385.9)
Pancreas				
Male	1	2.8	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)
Prostate				
Male	30	31.3	95.9	(64.7-137)
Stomach				
Male	0	2	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Testis				
Male	2	0.9	nc	(nc-nc)
Thyroid				
Male	1	1.9	nc	(nc-nc)
Female	2	5.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	9	7.5	119.4	(54.5-226.7)
All Sites / Types				
Male	103	113.1	91	(74.3-110.4)
Female	109	115.4	94.4	(77.5-113.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	41	33.8	121.3	(87.1-164.6)
Female	10	13.1	76.2	(36.5-140.1)
Brain and Other Nervous System				
Male	9	6	150.8	(68.8-286.2)
Female	3	5.3	nc	(nc-nc)
Breast				
Male	0	1	nc	(nc-nc)
Female	135	129.6	104.2	(87.3-123.3)
Cervix Uteri				
Female	4	4.4	nc	(nc-nc)
Colon / Rectum				
Male	31	37.5	82.7	(56.2-117.4)
Female	46	41.4	111.1	(81.4-148.3)
Esophagus				
Male	11	8.8	124.8	(62.2-223.3)
Female	3	2.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	2.3	nc	(nc-nc)
Female	5	2	249.6	(80.4-582.5)
Kidney & Renal Pelvis				
Male	28	17.1	163.7	(108.7-236.6)
Female	9	10.6	85.2	(38.9-161.8)
Larynx				
Male	2	4.8	nc	(nc-nc)
Female	2	1.5	nc	(nc-nc)
Leukemia				
Male	15	12.6	118.9	(66.5-196.1)
Female	17	9.9	171.6	(99.9-274.8)
Liver and Intrahepatic Bile Ducts				
Male	13	10.1	128.6	(68.4-219.9)
Female	6	3.8	159.8	(58.4-347.9)
Lung and Bronchus				
Male	75	60.9	123.2	(96.9-154.5)
Female	63	65.9	95.6	(73.5-122.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	26	21.2	122.9	(80.2-180)
Female	21	17.3	121.5	(75.2-185.8)
Multiple Myeloma				
Male	4	6	nc	(nc-nc)
Female	3	5.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	15	18.7	80.4	(44.9-132.5)
Female	30	16.6	180.9	(122-258.3)
Oral Cavity & Pharynx				
Male	13	13.8	94.5	(50.3-161.6)
Female	5	6.5	77.1	(24.9-180)
Ovary				
Female	9	11.9	75.6	(34.5-143.5)
Pancreas				
Male	15	11	136.4	(76.3-225)
Female	17	12.8	133.2	(77.5-213.2)
Prostate				
Male	144	120.8	119.2	(100.5-140.3)
Stomach				
Male	3	7.9	nc	(nc-nc)
Female	3	5.1	nc	(nc-nc)
Testis				
Male	8	3.5	230.7	(99.3-454.6)
Thyroid				
Male	10	7.2	138.8	(66.4-255.2)
Female	20	22.4	89.4	(54.6-138.2)
Uteri Corpus and Uterus, NOS				
Female	39	29.5	132.3	(94-180.8)
All Sites / Types				
Male	504	438.7	114.9	(105.1-125.4)
Female	484	454.6	106.5	(97.2-116.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	55	38.7	142.2	(107.1-185.1)
Female	21	14.1	148.8	(92.1-227.5)
Brain and Other Nervous System				
Male	7	7.2	97.9	(39.2-201.7)
Female	4	5.9	nc	(nc-nc)
Breast				
Male	2	1.2	nc	(nc-nc)
Female	118	140.9	83.8	(69.3-100.3)
Cervix Uteri				
Female	5	4.8	104.5	(33.7-243.9)
Colon / Rectum				
Male	42	43.2	97.2	(70-131.4)
Female	46	44.4	103.6	(75.9-138.2)
Esophagus				
Male	13	10.2	127	(67.6-217.2)
Female	3	2.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	4	3.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	27	19.9	135.5	(89.3-197.2)
Female	15	11.5	130.6	(73.1-215.5)
Larynx				
Male	6	5.6	107.8	(39.4-234.6)
Female	0	1.7	nc	(nc-nc)
Leukemia				
Male	20	14.8	134.9	(82.4-208.4)
Female	10	10.7	93.1	(44.6-171.2)
Liver and Intrahepatic Bile Ducts				
Male	4	11.7	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)
Lung and Bronchus				
Male	79	69.8	113.2	(89.6-141.1)
Female	45	71.4	63	(45.9-84.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	17	24.7	68.8	(40.1-110.2)
Female	19	19.1	99.6	(59.9-155.6)
Multiple Myeloma				
Male	5	6.9	72.7	(23.4-169.7)
Female	5	5.6	88.9	(28.6-207.4)
Non-Hodgkin Lymphoma				
Male	21	21.9	96	(59.4-146.8)
Female	22	18	122.2	(76.6-185.1)
Oral Cavity & Pharynx				
Male	17	16.1	105.3	(61.3-168.7)
Female	8	7.1	113.4	(48.8-223.4)
Ovary				
Female	11	13	84.5	(42.1-151.2)
Pancreas				
Male	11	12.6	87.1	(43.4-155.8)
Female	9	13.7	65.7	(30-124.8)
Prostate				
Male	205	141.4	145	(125.8-166.2)
Stomach				
Male	16	9.1	176.2	(100.6-286.1)
Female	3	5.5	nc	(nc-nc)
Testis				
Male	3	5.1	nc	(nc-nc)
Thyroid				
Male	11	8.7	125.9	(62.7-225.2)
Female	26	25	103.9	(67.8-152.2)
Uteri Corpus and Uterus, NOS				
Female	34	32.3	105.2	(72.8-147)
All Sites / Types				
Male	608	511.4	118.9	(109.6-128.7)
Female	454	494.3	91.9	(83.6-100.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	34	31.9	106.4	(73.7-148.7)
Female	9	11.9	75.7	(34.5-143.7)
Brain and Other Nervous System				
Male	7	5.6	124.9	(50-257.3)
Female	6	4.8	125.5	(45.8-273.1)
Breast				
Male	1	1	nc	(nc-nc)
Female	117	116	100.8	(83.4-120.9)
Cervix Uteri				
Female	7	3.9	178.3	(71.4-367.4)
Colon / Rectum				
Male	30	35.2	85.2	(57.4-121.6)
Female	36	37.3	96.4	(67.5-133.5)
Esophagus				
Male	7	8.2	85.4	(34.2-175.9)
Female	2	2.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	2.2	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	15.8	63.1	(30.2-116.1)
Female	14	9.5	146.9	(80.2-246.5)
Larynx				
Male	2	4.4	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Leukemia				
Male	9	12	75.2	(34.3-142.8)
Female	5	9	55.8	(18-130.2)
Liver and Intrahepatic Bile Ducts				
Male	10	9.3	107.1	(51.3-197)
Female	3	3.4	nc	(nc-nc)
Lung and Bronchus				
Male	58	56.9	101.9	(77.4-131.8)
Female	70	59.7	117.2	(91.3-148)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	19	19.8	95.8	(57.6-149.6)
Female	22	15.5	141.7	(88.8-214.6)
Multiple Myeloma				
Male	4	5.6	nc	(nc-nc)
Female	1	4.7	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	18	17.6	102.5	(60.7-161.9)
Female	13	15	86.9	(46.2-148.6)
Oral Cavity & Pharynx				
Male	12	12.7	94.5	(48.8-165.1)
Female	3	5.8	nc	(nc-nc)
Ovary				
Female	11	10.7	103	(51.3-184.3)
Pancreas				
Male	8	10.3	77.4	(33.3-152.5)
Female	14	11.6	121	(66.1-203)
Prostate				
Male	84	111	75.7	(60.4-93.7)
Stomach				
Male	9	7.4	121.5	(55.4-230.7)
Female	5	4.6	108	(34.8-251.9)
Testis				
Male	2	3.5	nc	(nc-nc)
Thyroid				
Male	5	6.7	74.3	(24-173.4)
Female	26	20	130.1	(85-190.7)
Uteri Corpus and Uterus, NOS				
Female	22	26.5	83.1	(52.1-125.9)
All Sites / Types				
Male	361	409.5	88.2	(79.3-97.7)
Female	421	409.2	102.9	(93.3-113.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	6.1	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	1.2	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	19	23.4	81.2	(48.9-126.9)
Cervix Uteri				
Female	0	0.8	nc	(nc-nc)
Colon / Rectum				
Male	6	7	85.5	(31.2-186.1)
Female	1	6.5	nc	(nc-nc)
Esophagus				
Male	1	1.7	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	5	3.4	147.2	(47.4-343.4)
Female	3	1.8	nc	(nc-nc)
Larynx				
Male	0	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	0	2.4	nc	(nc-nc)
Female	1	1.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	5	11.4	44	(14.2-102.7)
Female	2	10.9	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	4.1	123.2	(39.7-287.5)
Female	3	3.1	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.1	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	3.5	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.8	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)
Ovary				
Female	0	2.1	nc	(nc-nc)
Pancreas				
Male	0	2	nc	(nc-nc)
Female	1	2	nc	(nc-nc)
Prostate				
Male	31	24.7	125.7	(85.4-178.5)
Stomach				
Male	1	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Testis				
Male	3	0.7	nc	(nc-nc)
Thyroid				
Male	2	1.5	nc	(nc-nc)
Female	3	4.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	5.5	nc	(nc-nc)
All Sites / Types				
Male	73	84.9	86	(67.4-108.1)
Female	50	78.2	63.9	(47.4-84.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	34	32.6	104.2	(72.1-145.6)
Female	14	11.2	125.2	(68.4-210)
Brain and Other Nervous System				
Male	5	4.5	111.4	(35.9-260)
Female	3	3.9	nc	(nc-nc)
Breast				
Male	1	1	nc	(nc-nc)
Female	126	98.8	127.5	(106.2-151.8)
Cervix Uteri				
Female	1	2.9	nc	(nc-nc)
Colon / Rectum				
Male	38	33.4	113.8	(80.5-156.2)
Female	33	33.6	98.1	(67.6-137.8)
Esophagus				
Male	10	7.9	126.1	(60.4-232)
Female	4	2.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.4	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	10	14.1	71	(34-130.6)
Female	11	8.6	128.4	(64-229.8)
Larynx				
Male	3	4.2	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Leukemia				
Male	9	11	81.5	(37.2-154.7)
Female	8	7.7	103.9	(44.7-204.7)
Liver and Intrahepatic Bile Ducts				
Male	8	8.4	94.8	(40.8-186.9)
Female	3	3.1	nc	(nc-nc)
Lung and Bronchus				
Male	48	57.9	83	(61.2-110)
Female	56	57.8	96.9	(73.2-125.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	37	18.3	201.8	(142-278.1)
Female	32	12.8	251	(171.6-354.3)
Multiple Myeloma				
Male	4	5.4	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	16	16.1	99.1	(56.6-161)
Female	14	13.5	103.8	(56.7-174.2)
Oral Cavity & Pharynx				
Male	23	10.9	210.8	(133.6-316.4)
Female	3	5.1	nc	(nc-nc)
Ovary				
Female	7	9.3	75.4	(30.2-155.3)
Pancreas				
Male	12	10.3	116.7	(60.3-203.9)
Female	9	10.9	82.8	(37.8-157.3)
Prostate				
Male	134	106.3	126.1	(105.6-149.3)
Stomach				
Male	3	7.2	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)
Testis				
Male	1	1.7	nc	(nc-nc)
Thyroid				
Male	2	5.1	nc	(nc-nc)
Female	16	14	114	(65.1-185.1)
Uteri Corpus and Uterus, NOS				
Female	22	23.5	93.8	(58.7-142)
All Sites / Types				
Male	435	388.8	111.9	(101.6-122.9)
Female	402	360.2	111.6	(101-123.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	8	7.2	110.7	(47.6-218.1)
Female	1	2.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	20	28.3	70.6	(43.1-109.1)
Cervix Uteri				
Female	1	1	nc	(nc-nc)
Colon / Rectum				
Male	10	8.4	118.5	(56.7-218)
Female	2	8.1	nc	(nc-nc)
Esophagus				
Male	1	2	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	7	4.1	172	(68.9-354.5)
Female	4	2.2	nc	(nc-nc)
Larynx				
Male	1	1.1	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)
Leukemia				
Male	0	2.9	nc	(nc-nc)
Female	3	2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	2.4	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Lung and Bronchus				
Male	8	13.3	60.1	(25.9-118.5)
Female	13	13.1	99.3	(52.8-169.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	5	4.9	102.8	(33.1-239.9)
Female	5	3.8	132	(42.5-308)
Multiple Myeloma				
Male	1	1.3	nc	(nc-nc)
Female	2	1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	4.3	140.4	(51.3-305.6)
Female	1	3.4	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	3.3	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Ovary				
Female	2	2.5	nc	(nc-nc)
Pancreas				
Male	5	2.4	207	(66.7-483)
Female	1	2.4	nc	(nc-nc)
Prostate				
Male	29	28.5	101.7	(68.1-146)
Stomach				
Male	2	1.8	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Testis				
Male	2	1	nc	(nc-nc)
Thyroid				
Male	5	1.8	271.9	(87.6-634.5)
Female	6	5.5	109.6	(40-238.6)
Uteri Corpus and Uterus, NOS				
Female	4	6.4	nc	(nc-nc)
All Sites / Types				
Male	102	100.6	101.4	(82.7-123.1)
Female	79	95.2	83	(65.7-103.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	9	6	151.1	(69-286.9)
Female	3	2	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Breast				
Male	1	0.2	nc	(nc-nc)
Female	32	26.9	118.9	(81.3-167.8)
Cervix Uteri				
Female	0	1.2	nc	(nc-nc)
Colon / Rectum				
Male	8	7.6	105.5	(45.4-208)
Female	2	6.7	nc	(nc-nc)
Esophagus				
Male	4	1.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	0.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	6	4	151.1	(55.2-328.9)
Female	1	2	nc	(nc-nc)
Larynx				
Male	1	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	1	2.6	nc	(nc-nc)
Female	4	1.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	2.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	10	11.2	88.9	(42.6-163.5)
Female	17	10.6	160.4	(93.4-256.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	4.6	131.8	(48.1-286.8)
Female	8	3.7	215.1	(92.6-423.8)
Multiple Myeloma				
Male	1	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	5	4	125	(40.3-291.7)
Female	1	2.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	3.3	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Ovary				
Female	1	2.3	nc	(nc-nc)
Pancreas				
Male	4	2.1	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Prostate				
Male	24	25.7	93.2	(59.7-138.7)
Stomach				
Male	1	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Testis				
Male	2	1.3	nc	(nc-nc)
Thyroid				
Male	1	2	nc	(nc-nc)
Female	5	6.2	80.8	(26.1-188.7)
Uteri Corpus and Uterus, NOS				
Female	9	5.9	153.2	(69.9-290.9)
All Sites / Types				
Male	100	91.1	109.7	(89.3-133.4)
Female	94	86.4	108.8	(87.9-133.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	3	6.5	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	1.3	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	23	23.8	96.6	(61.2-144.9)
Cervix Uteri				
Female	0	0.8	nc	(nc-nc)
Colon / Rectum				
Male	5	7.6	66	(21.3-154.1)
Female	5	5.9	84.3	(27.2-196.8)
Esophagus				
Male	3	1.9	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	3.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Larynx				
Male	0	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Leukemia				
Male	3	2.5	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	2.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Lung and Bronchus				
Male	4	12.2	nc	(nc-nc)
Female	8	10.3	77.5	(33.4-152.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	7	4.4	160.9	(64.5-331.5)
Female	2	3	nc	(nc-nc)
Multiple Myeloma				
Male	0	1.2	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	9	3.8	237.1	(108.2-450.1)
Female	1	2.6	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	3	3.1	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Ovary				
Female	0	2.1	nc	(nc-nc)
Pancreas				
Male	1	2.2	nc	(nc-nc)
Female	3	1.8	nc	(nc-nc)
Prostate				
Male	32	26.8	119.3	(81.6-168.5)
Stomach				
Male	0	1.6	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Testis				
Male	1	0.6	nc	(nc-nc)
Thyroid				
Male	4	1.6	nc	(nc-nc)
Female	8	4.4	180.1	(77.6-355)
Uteri Corpus and Uterus, NOS				
Female	4	5.6	nc	(nc-nc)
All Sites / Types				
Male	89	91.5	97.3	(78.1-119.7)
Female	70	76.1	92	(71.7-116.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	42	28.3	148.5	(107-200.7)
Female	23	10.2	226.5	(143.6-339.9)
Brain and Other Nervous System				
Male	10	6	166.4	(79.7-306)
Female	6	4.9	122.7	(44.8-267.1)
Breast				
Male	0	0.9	nc	(nc-nc)
Female	131	116.9	112.1	(93.7-133)
Cervix Uteri				
Female	7	4.4	158.4	(63.5-326.4)
Colon / Rectum				
Male	47	32.9	142.8	(104.9-189.9)
Female	37	32.1	115.2	(81.1-158.7)
Esophagus				
Male	11	7.9	139.1	(69.3-248.9)
Female	1	2.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	2.6	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	20	16.2	123.4	(75.3-190.6)
Female	8	9.2	87.1	(37.5-171.7)
Larynx				
Male	3	4.4	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)
Leukemia				
Male	24	11.4	210.8	(135-313.7)
Female	11	8.3	132.7	(66.2-237.5)
Liver and Intrahepatic Bile Ducts				
Male	6	9.4	63.9	(23.3-139.1)
Female	2	3.1	nc	(nc-nc)
Lung and Bronchus				
Male	61	52.6	116	(88.7-149)
Female	68	54.4	125.1	(97.1-158.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	8	19.4	41.3	(17.8-81.3)
Female	18	15.8	114.2	(67.6-180.4)
Multiple Myeloma				
Male	6	5.3	114	(41.6-248.2)
Female	4	4.2	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	21	17	123.6	(76.5-189)
Female	11	13.8	80	(39.9-143.1)
Oral Cavity & Pharynx				
Male	9	13.1	68.5	(31.2-130)
Female	6	5.6	107.7	(39.3-234.5)
Ovary				
Female	14	10.4	134.5	(73.5-225.7)
Pancreas				
Male	6	9.4	63.5	(23.2-138.2)
Female	12	9.7	123.5	(63.8-215.8)
Prostate				
Male	98	111.6	87.8	(71.3-107)
Stomach				
Male	3	6.9	nc	(nc-nc)
Female	6	3.9	154.7	(56.5-336.8)
Testis				
Male	1	4.4	nc	(nc-nc)
Thyroid				
Male	5	7.5	66.7	(21.5-155.7)
Female	28	23.3	120.2	(79.8-173.7)
Uteri Corpus and Uterus, NOS				
Female	20	26.7	75	(45.8-115.8)
All Sites / Types				
Male	417	396.5	105.2	(95.3-115.8)
Female	451	391.8	115.1	(104.7-126.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	12	11.1	108	(55.8-188.7)
Female	3	3.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	2	2.3	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Breast				
Male	1	0.4	nc	(nc-nc)
Female	34	42.4	80.3	(55.6-112.2)
Cervix Uteri				
Female	0	1.6	nc	(nc-nc)
Colon / Rectum				
Male	15	12.8	117.1	(65.5-193.2)
Female	13	12.1	107.7	(57.3-184.2)
Esophagus				
Male	6	3	197.4	(72.1-429.7)
Female	2	0.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	4	6.1	nc	(nc-nc)
Female	3	3.3	nc	(nc-nc)
Larynx				
Male	3	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Leukemia				
Male	6	4.5	134.7	(49.2-293.3)
Female	4	3.1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	3.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Lung and Bronchus				
Male	24	20.3	118.2	(75.7-175.9)
Female	20	19.7	101.8	(62.1-157.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	2	7.4	nc	(nc-nc)
Female	4	5.8	nc	(nc-nc)
Multiple Myeloma				
Male	0	2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	6.6	nc	(nc-nc)
Female	4	5.1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	5	nc	(nc-nc)
Female	1	2	nc	(nc-nc)
Ovary				
Female	8	3.8	209.8	(90.3-413.4)
Pancreas				
Male	5	3.7	135.8	(43.8-317)
Female	3	3.6	nc	(nc-nc)
Prostate				
Male	38	42.4	89.6	(63.4-123)
Stomach				
Male	2	2.7	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)
Testis				
Male	2	1.7	nc	(nc-nc)
Thyroid				
Male	0	2.8	nc	(nc-nc)
Female	9	8.4	106.8	(48.8-202.8)
Uteri Corpus and Uterus, NOS				
Female	14	9.6	146	(79.8-245.1)
All Sites / Types				
Male	144	152.6	94.4	(79.6-111.1)
Female	137	143.2	95.7	(80.3-113.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	2	2.6	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	8	11.9	67	(28.8-132)
Cervix Uteri				
Female	0	0.5	nc	(nc-nc)
Colon / Rectum				
Male	5	3.3	150.8	(48.6-351.8)
Female	2	2.7	nc	(nc-nc)
Esophagus				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	3	1.8	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Larynx				
Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	3	1.1	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Lung and Bronchus				
Male	3	5.1	nc	(nc-nc)
Female	2	4.6	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	2	nc	(nc-nc)
Female	1	1.5	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	1.5	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Ovary				
Female	0	1	nc	(nc-nc)
Pancreas				
Male	1	0.9	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)
Prostate				
Male	8	12.1	66	(28.4-130)
Stomach				
Male	0	0.7	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)
Testis				
Male	1	0.4	nc	(nc-nc)
Thyroid				
Male	0	0.8	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	2.7	nc	(nc-nc)
All Sites / Types				
Male	36	40.7	88.4	(61.9-122.4)
Female	28	36.9	75.9	(50.4-109.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	18	17.3	103.9	(61.6-164.3)
Female	1	6.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	4	3.4	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)
Breast				
Male	0	0.6	nc	(nc-nc)
Female	72	68.9	104.5	(81.8-131.6)
Cervix Uteri				
Female	0	2.4	nc	(nc-nc)
Colon / Rectum				
Male	14	20.1	69.7	(38.1-117)
Female	12	20.2	59.5	(30.7-103.9)
Esophagus				
Male	8	4.9	163.8	(70.5-322.9)
Female	0	1.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.2	nc	(nc-nc)
Female	3	1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	9.7	124.2	(64.1-217)
Female	3	5.4	nc	(nc-nc)
Larynx				
Male	0	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Leukemia				
Male	5	6.7	74.2	(23.9-173.1)
Female	4	5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	2	5.8	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Lung and Bronchus				
Male	22	32	68.7	(43.1-104.1)
Female	18	31.9	56.4	(33.4-89.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	31	11.4	271.3	(184.3-385.1)
Female	14	8.9	157.4	(86-264.1)
Multiple Myeloma				
Male	4	3.2	nc	(nc-nc)
Female	3	2.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	11	10	109.9	(54.8-196.6)
Female	6	8.2	72.8	(26.6-158.4)
Oral Cavity & Pharynx				
Male	5	8	62.4	(20.1-145.7)
Female	3	3.3	nc	(nc-nc)
Ovary				
Female	11	6.2	177.5	(88.5-317.6)
Pancreas				
Male	4	5.8	nc	(nc-nc)
Female	4	6.1	nc	(nc-nc)
Prostate				
Male	87	69.7	124.9	(100-154)
Stomach				
Male	2	4.2	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Testis				
Male	2	1.7	nc	(nc-nc)
Thyroid				
Male	2	4.1	nc	(nc-nc)
Female	16	12.1	132.1	(75.5-214.6)
Uteri Corpus and Uterus, NOS				
Female	10	15.8	63.2	(30.3-116.2)
All Sites / Types				
Male	258	240.2	107.4	(94.7-121.3)
Female	209	231.7	90.2	(78.4-103.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	14	13	107.3	(58.6-180.1)
Female	8	4.7	170.7	(73.5-336.3)
Brain and Other Nervous System				
Male	2	2.8	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)
Breast				
Male	0	0.4	nc	(nc-nc)
Female	56	54.9	102.1	(77.1-132.6)
Cervix Uteri				
Female	2	2.1	nc	(nc-nc)
Colon / Rectum				
Male	13	15.4	84.6	(45-144.6)
Female	16	14.9	107.4	(61.3-174.3)
Esophagus				
Male	2	3.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	1.2	nc	(nc-nc)
Female	1	1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	7.7	155.9	(80.4-272.3)
Female	4	4.3	nc	(nc-nc)
Larynx				
Male	3	2.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Leukemia				
Male	3	5.3	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	4.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Lung and Bronchus				
Male	34	24.5	138.5	(95.9-193.6)
Female	29	24.9	116.6	(78.1-167.4)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	12	9.1	132.2	(68.3-231)
Female	13	7.4	176.5	(93.9-301.9)
Multiple Myeloma				
Male	1	2.5	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	8	7.9	101	(43.5-199.1)
Female	11	6.4	171.8	(85.6-307.4)
Oral Cavity & Pharynx				
Male	7	6.3	110.9	(44.4-228.5)
Female	2	2.6	nc	(nc-nc)
Ovary				
Female	3	4.9	nc	(nc-nc)
Pancreas				
Male	5	4.4	113.1	(36.4-263.9)
Female	6	4.5	133.8	(48.9-291.2)
Prostate				
Male	48	53.7	89.4	(65.9-118.6)
Stomach				
Male	5	3.2	156.2	(50.3-364.5)
Female	0	1.8	nc	(nc-nc)
Testis				
Male	2	2	nc	(nc-nc)
Thyroid				
Male	5	3.6	140.1	(45.1-326.9)
Female	14	10.9	128.2	(70-215.1)
Uteri Corpus and Uterus, NOS				
Female	18	12.6	142.5	(84.4-225.2)
All Sites / Types				
Male	197	186.9	105.4	(91.2-121.2)
Female	209	182.6	114.4	(99.5-131.1)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	3	2.5	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	7	8.8	80	(32-164.8)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	4	2.9	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)
Esophagus				
Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Larynx				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	1	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	1	4.6	nc	(nc-nc)
Female	4	4.1	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	3	1.7	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)
Multiple Myeloma				
Male	2	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.4	nc	(nc-nc)
Female	1	1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1.1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Ovary				
Female	0	0.8	nc	(nc-nc)
Pancreas				
Male	0	0.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Prostate				
Male	8	9.9	80.6	(34.7-158.8)
Stomach				
Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Testis				
Male	0	0.3	nc	(nc-nc)
Thyroid				
Male	1	0.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	2	nc	(nc-nc)
All Sites / Types				
Male	29	34.6	83.9	(56.2-120.5)
Female	31	29.4	105.5	(71.7-149.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	20	21.3	93.9	(57.3-145)
Female	5	8.4	59.5	(19.2-138.8)
Brain and Other Nervous System				
Male	3	3.6	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)
Breast				
Male	0	0.7	nc	(nc-nc)
Female	62	77.3	80.3	(61.5-102.9)
Cervix Uteri				
Female	1	2.5	nc	(nc-nc)
Colon / Rectum				
Male	18	23.4	76.9	(45.6-121.5)
Female	23	26.6	86.6	(54.9-129.9)
Esophagus				
Male	1	5.4	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	1.3	nc	(nc-nc)
Female	3	1.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	11	10.3	106.3	(53-190.3)
Female	8	6.4	125	(53.8-246.3)
Larynx				
Male	4	2.9	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)
Leukemia				
Male	9	7.9	114.3	(52.2-217.1)
Female	0	6.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	3	6.1	nc	(nc-nc)
Female	0	2.3	nc	(nc-nc)
Lung and Bronchus				
Male	31	37.7	82.2	(55.8-116.7)
Female	42	40.7	103.2	(74.4-139.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	17	13	131	(76.3-209.8)
Female	7	10.3	67.9	(27.2-139.9)
Multiple Myeloma				
Male	0	3.7	nc	(nc-nc)
Female	1	3.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	11	11.5	95.4	(47.5-170.6)
Female	10	10.3	97	(46.4-178.4)
Oral Cavity & Pharynx				
Male	9	8.3	108.4	(49.4-205.7)
Female	5	3.9	126.7	(40.8-295.7)
Ovary				
Female	8	7.2	111.4	(48-219.6)
Pancreas				
Male	6	6.9	87.5	(31.9-190.4)
Female	13	8.2	157.7	(83.9-269.7)
Prostate				
Male	79	72.9	108.3	(85.8-135)
Stomach				
Male	4	4.9	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)
Testis				
Male	1	1.9	nc	(nc-nc)
Thyroid				
Male	3	4.3	nc	(nc-nc)
Female	8	12.6	63.6	(27.4-125.2)
Uteri Corpus and Uterus, NOS				
Female	9	17.3	52.1	(23.8-99)
All Sites / Types				
Male	248	269.5	92	(80.9-104.2)
Female	233	277.5	84	(73.5-95.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	11.8	59.4	(23.8-122.4)
Female	5	3.5	140.9	(45.4-328.7)
Brain and Other Nervous System				
Male	1	1.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Breast				
Male	0	0.3	nc	(nc-nc)
Female	40	33.1	120.9	(86.4-164.6)
Cervix Uteri				
Female	0	1	nc	(nc-nc)
Colon / Rectum				
Male	7	12.1	58	(23.2-119.6)
Female	11	10.6	104.2	(51.9-186.4)
Esophagus				
Male	0	2.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.5	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	7	5.1	136.8	(54.8-281.8)
Female	0	2.8	nc	(nc-nc)
Larynx				
Male	0	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Leukemia				
Male	9	4	226	(103.1-429)
Female	3	2.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	3.1	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Lung and Bronchus				
Male	17	21	81.1	(47.2-129.9)
Female	14	18.9	74.2	(40.5-124.5)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	6.6	150.6	(72.1-277)
Female	16	4.2	379.1	(216.6-615.7)
Multiple Myeloma				
Male	3	2	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	4	5.8	nc	(nc-nc)
Female	5	4.4	114.6	(36.9-267.4)
Oral Cavity & Pharynx				
Male	3	4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Ovary				
Female	7	3.1	228.3	(91.5-470.4)
Pancreas				
Male	3	3.7	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)
Prostate				
Male	51	38.7	131.9	(98.2-173.4)
Stomach				
Male	2	2.6	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)
Testis				
Male	0	0.6	nc	(nc-nc)
Thyroid				
Male	0	1.8	nc	(nc-nc)
Female	3	4.9	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	10	8	125.6	(60.1-230.9)
All Sites / Types				
Male	136	140.9	96.5	(81-114.2)
Female	134	118.1	113.5	(95.1-134.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	13	18.3	71	(37.8-121.4)
Female	4	6.9	nc	(nc-nc)
Brain and Other Nervous System				
Male	3	3.5	nc	(nc-nc)
Female	5	3	168.2	(54.2-392.5)
Breast				
Male	0	0.6	nc	(nc-nc)
Female	75	72.4	103.5	(81.4-129.8)
Cervix Uteri				
Female	2	2.6	nc	(nc-nc)
Colon / Rectum				
Male	27	21	128.7	(84.8-187.3)
Female	28	21.9	128.1	(85.1-185.1)
Esophagus				
Male	6	4.9	121.6	(44.4-264.6)
Female	2	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	9.8	81.7	(35.2-161)
Female	10	5.8	172.9	(82.8-318.1)
Larynx				
Male	4	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Leukemia				
Male	6	7.1	84.8	(31-184.6)
Female	4	5.3	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	1	5.8	nc	(nc-nc)
Female	3	2	nc	(nc-nc)
Lung and Bronchus				
Male	33	33.1	99.8	(68.7-140.1)
Female	30	35	85.6	(57.8-122.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	6	12	50	(18.3-108.9)
Female	7	9.9	70.8	(28.4-145.9)
Multiple Myeloma				
Male	3	3.3	nc	(nc-nc)
Female	3	2.8	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	6	10.6	56.8	(20.8-123.7)
Female	5	9	55.8	(18-130.1)
Oral Cavity & Pharynx				
Male	7	8	87	(34.9-179.3)
Female	7	3.6	195.5	(78.3-402.8)
Ovary				
Female	6	6.6	90.7	(33.1-197.5)
Pancreas				
Male	4	6	nc	(nc-nc)
Female	6	6.6	90.2	(33-196.4)
Prostate				
Male	75	68.3	109.8	(86.4-137.7)
Stomach				
Male	5	4.4	114.4	(36.9-267.1)
Female	1	2.7	nc	(nc-nc)
Testis				
Male	1	2.5	nc	(nc-nc)
Thyroid				
Male	1	4.4	nc	(nc-nc)
Female	13	13.7	94.7	(50.4-162)
Uteri Corpus and Uterus, NOS				
Female	14	16.6	84.2	(46-141.3)
All Sites / Types				
Male	226	246.5	91.7	(80.1-104.4)
Female	240	249.8	96.1	(84.3-109)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	21	20.9	100.4	(62.1-153.4)
Female	9	7.1	126.7	(57.8-240.6)
Brain and Other Nervous System				
Male	7	4.6	152.9	(61.2-315)
Female	6	3.6	164.4	(60-357.9)
Breast				
Male	3	0.7	nc	(nc-nc)
Female	117	87	134.4	(111.2-161.1)
Cervix Uteri				
Female	1	3.3	nc	(nc-nc)
Colon / Rectum				
Male	22	24.9	88.5	(55.4-133.9)
Female	33	22.9	144.1	(99.2-202.4)
Esophagus				
Male	8	6	132.3	(57-260.7)
Female	2	1.4	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	2	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	12.5	96.4	(49.7-168.3)
Female	11	6.6	165.6	(82.5-296.3)
Larynx				
Male	3	3.4	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Leukemia				
Male	10	8.6	116.8	(55.9-214.8)
Female	8	6	132.7	(57.1-261.4)
Liver and Intrahepatic Bile Ducts				
Male	8	7.3	109.9	(47.3-216.5)
Female	1	2.2	nc	(nc-nc)
Lung and Bronchus				
Male	37	39.3	94.3	(66.4-129.9)
Female	33	37.8	87.3	(60.1-122.6)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	17	14.7	116	(67.6-185.8)
Female	20	11.8	169.6	(103.6-262)
Multiple Myeloma				
Male	5	4	126.3	(40.7-294.7)
Female	3	2.9	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	10	12.8	78	(37.3-143.4)
Female	14	9.9	141.3	(77.2-237.1)
Oral Cavity & Pharynx				
Male	5	10.3	48.6	(15.7-113.4)
Female	2	4.1	nc	(nc-nc)
Ovary				
Female	10	7.7	129.1	(61.8-237.5)
Pancreas				
Male	5	7.1	70.5	(22.7-164.6)
Female	9	6.8	133.1	(60.7-252.7)
Prostate				
Male	71	87	81.6	(63.7-102.9)
Stomach				
Male	6	5.2	116.1	(42.4-252.6)
Female	1	2.8	nc	(nc-nc)
Testis				
Male	6	3.3	181.4	(66.2-394.8)
Thyroid				
Male	9	5.8	155.5	(71-295.3)
Female	23	18	127.9	(81.1-192)
Uteri Corpus and Uterus, NOS				
Female	19	20	95.2	(57.3-148.7)
All Sites / Types				
Male	287	302.2	95	(84.3-106.6)
Female	351	286	122.7	(110.2-136.3)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	3	5	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	1	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Breast				
Male	0	0.2	nc	(nc-nc)
Female	11	17.7	62.3	(31-111.4)
Cervix Uteri				
Female	1	0.6	nc	(nc-nc)
Colon / Rectum				
Male	4	5.7	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)
Esophagus				
Male	2	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	0.4	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	2	2.8	nc	(nc-nc)
Female	0	1.4	nc	(nc-nc)
Larynx				
Male	0	0.8	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Leukemia				
Male	2	1.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.7	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Lung and Bronchus				
Male	7	9.3	75	(30-154.5)
Female	13	8.3	156.2	(83.1-267.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	9	3.4	268.3	(122.4-509.3)
Female	4	2.3	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.9	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	2.9	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	2	2.3	nc	(nc-nc)
Female	3	0.8	nc	(nc-nc)
Ovary				
Female	0	1.6	nc	(nc-nc)
Pancreas				
Male	0	1.7	nc	(nc-nc)
Female	4	1.5	nc	(nc-nc)
Prostate				
Male	29	20.4	142.3	(95.3-204.4)
Stomach				
Male	2	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Testis				
Male	1	0.6	nc	(nc-nc)
Thyroid				
Male	0	1.2	nc	(nc-nc)
Female	4	3.3	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	5	4.2	119.4	(38.5-278.7)
All Sites / Types				
Male	72	69.9	103	(80.6-129.7)
Female	64	58.8	108.9	(83.8-139)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	1	2.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	6	7.7	78.1	(28.5-170.1)
Cervix Uteri				
Female	0	0.2	nc	(nc-nc)
Colon / Rectum				
Male	2	2.6	nc	(nc-nc)
Female	3	2.2	nc	(nc-nc)
Esophagus				
Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Larynx				
Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	3	4.5	nc	(nc-nc)
Female	2	3.9	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	1.5	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.3	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	1	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Ovary				
Female	0	0.7	nc	(nc-nc)
Pancreas				
Male	1	0.8	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)
Prostate				
Male	5	9	55.4	(17.9-129.4)
Stomach				
Male	0	0.6	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Testis				
Male	0	0.2	nc	(nc-nc)
Thyroid				
Male	0	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	0	1.9	nc	(nc-nc)
All Sites / Types				
Male	22	31.2	70.5	(44.1-106.7)
Female	16	26.1	61.4	(35.1-99.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	0	2.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	5	7.2	69.3	(22.3-161.7)
Cervix Uteri				
Female	0	0.3	nc	(nc-nc)
Colon / Rectum				
Male	5	2.3	214.2	(69-499.8)
Female	1	2	nc	(nc-nc)
Esophagus				
Male	2	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	1.1	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Larynx				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Leukemia				
Male	0	0.8	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Lung and Bronchus				
Male	4	3.7	nc	(nc-nc)
Female	1	3.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	1	1.3	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	0	1.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	0	0.9	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)
Ovary				
Female	1	0.7	nc	(nc-nc)
Pancreas				
Male	0	0.7	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Prostate				
Male	5	7.8	64.1	(20.7-149.6)
Stomach				
Male	0	0.5	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Testis				
Male	2	0.3	nc	(nc-nc)
Thyroid				
Male	1	0.5	nc	(nc-nc)
Female	1	1.4	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	3	1.7	nc	(nc-nc)
All Sites / Types				
Male	23	27.7	83.1	(52.7-124.7)
Female	19	24.4	77.7	(46.8-121.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	7	4.2	167.5	(67.1-345.1)
Female	0	1.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	1	0.8	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)
Breast				
Male	0	0.1	nc	(nc-nc)
Female	7	14.8	47.4	(19-97.7)
Cervix Uteri				
Female	2	0.5	nc	(nc-nc)
Colon / Rectum				
Male	2	4.8	nc	(nc-nc)
Female	3	4.1	nc	(nc-nc)
Esophagus				
Male	0	1.2	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	1	2.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Larynx				
Male	1	0.6	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Leukemia				
Male	3	1.6	nc	(nc-nc)
Female	0	1	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	1.4	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Lung and Bronchus				
Male	11	7.8	141.9	(70.7-253.9)
Female	7	6.8	102.4	(41-211.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	4	2.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)
Multiple Myeloma				
Male	1	0.8	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	2	2.4	nc	(nc-nc)
Female	0	1.7	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	4	1.9	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)
Ovary				
Female	4	1.3	nc	(nc-nc)
Pancreas				
Male	0	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Prostate				
Male	8	16.5	48.6	(20.9-95.8)
Stomach				
Male	1	1	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)
Testis				
Male	0	0.5	nc	(nc-nc)
Thyroid				
Male	1	1	nc	(nc-nc)
Female	2	2.8	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	2	3.4	nc	(nc-nc)
All Sites / Types				
Male	54	57.6	93.7	(70.4-122.2)
Female	41	49.3	83.2	(59.7-112.9)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	33	37.8	87.2	(60-122.5)
Female	9	14.6	61.7	(28.2-117.2)
Brain and Other Nervous System				
Male	6	7.8	77.3	(28.2-168.3)
Female	6	6.7	89.5	(32.7-194.8)
Breast				
Male	3	1.2	nc	(nc-nc)
Female	132	153.5	86	(72-102)
Cervix Uteri				
Female	12	5.8	205.4	(106-358.8)
Colon / Rectum				
Male	42	42.8	98.2	(70.8-132.8)
Female	41	46.1	88.9	(63.8-120.6)
Esophagus				
Male	10	10	100.2	(48-184.3)
Female	1	3	nc	(nc-nc)
Hodgkin Lymphoma				
Male	3	3.6	nc	(nc-nc)
Female	5	3	167.5	(54-390.8)
Kidney & Renal Pelvis				
Male	27	20.2	133.4	(87.9-194.1)
Female	13	12.4	105	(55.9-179.6)
Larynx				
Male	3	5.5	nc	(nc-nc)
Female	4	1.8	nc	(nc-nc)
Leukemia				
Male	4	15.1	nc	(nc-nc)
Female	11	11.8	93.4	(46.6-167.2)
Liver and Intrahepatic Bile Ducts				
Male	16	11.6	138.1	(78.9-224.3)
Female	6	4.3	140.6	(51.3-306)
Lung and Bronchus				
Male	79	68.4	115.5	(91.4-143.9)
Female	100	75	133.3	(108.4-162.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	20	25.1	79.6	(48.6-123)
Female	8	21.5	37.2	(16-73.2)
Multiple Myeloma				
Male	9	6.8	132.5	(60.5-251.6)
Female	5	5.8	85.5	(27.6-199.5)
Non-Hodgkin Lymphoma				
Male	20	22.2	90.1	(55-139.2)
Female	16	19.2	83.4	(47.7-135.5)
Oral Cavity & Pharynx				
Male	17	16.1	105.6	(61.5-169.1)
Female	2	7.6	nc	(nc-nc)
Ovary				
Female	15	14	107.3	(60-177)
Pancreas				
Male	16	12.4	129.4	(73.9-210.1)
Female	15	14.1	106.3	(59.4-175.3)
Prostate				
Male	102	136.7	74.6	(60.8-90.6)
Stomach				
Male	17	9	189.6	(110.4-303.6)
Female	9	5.7	158.7	(72.4-301.2)
Testis				
Male	4	6.4	nc	(nc-nc)
Thyroid				
Male	10	9.5	105.8	(50.6-194.6)
Female	27	30.9	87.5	(57.7-127.3)
Uteri Corpus and Uterus, NOS				
Female	27	34.6	78.1	(51.4-113.6)
All Sites / Types				
Male	474	507.5	93.4	(85.2-102.2)
Female	496	533.7	92.9	(84.9-101.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	27	22.5	120.2	(79.2-174.9)
Female	13	9	144.7	(77-247.4)
Brain and Other Nervous System				
Male	1	3.8	nc	(nc-nc)
Female	5	3.4	148.1	(47.7-345.7)
Breast				
Male	2	0.7	nc	(nc-nc)
Female	84	82.3	102.1	(81.4-126.4)
Cervix Uteri				
Female	2	2.7	nc	(nc-nc)
Colon / Rectum				
Male	22	24.6	89.4	(56-135.4)
Female	32	28.3	112.9	(77.2-159.4)
Esophagus				
Male	4	5.7	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	1.5	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	12	11	109.6	(56.6-191.4)
Female	10	6.9	145.9	(69.9-268.4)
Larynx				
Male	6	3.1	193.6	(70.7-421.5)
Female	6	1	608.7	(222.3-1324.9)
Leukemia				
Male	12	8.3	144.9	(74.8-253)
Female	9	6.6	136.4	(62.2-259)
Liver and Intrahepatic Bile Ducts				
Male	4	6.5	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)
Lung and Bronchus				
Male	62	39.9	155.5	(119.3-199.4)
Female	62	43.7	142	(108.9-182.1)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	10	13.8	72.6	(34.8-133.6)
Female	17	11.1	153.1	(89.1-245.2)
Multiple Myeloma				
Male	9	3.9	229.9	(104.9-436.4)
Female	3	3.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	9	12.2	73.8	(33.7-140.1)
Female	11	11	99.7	(49.7-178.4)
Oral Cavity & Pharynx				
Male	8	8.8	91	(39.2-179.3)
Female	5	4.2	118.3	(38.1-276)
Ovary				
Female	6	7.7	77.9	(28.4-169.6)
Pancreas				
Male	7	7.2	96.7	(38.8-199.3)
Female	11	8.8	124.9	(62.3-223.5)
Prostate				
Male	95	77.7	122.3	(98.9-149.4)
Stomach				
Male	9	5.2	173.6	(79.2-329.5)
Female	3	3.6	nc	(nc-nc)
Testis				
Male	1	2.2	nc	(nc-nc)
Thyroid				
Male	5	4.6	109.6	(35.3-255.8)
Female	16	13.6	118	(67.4-191.6)
Uteri Corpus and Uterus, NOS				
Female	12	18.6	64.4	(33.3-112.6)
All Sites / Types				
Male	335	285.5	117.3	(105.1-130.6)
Female	339	296.8	114.2	(102.4-127)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	108	98.2	110	(90.2-132.8)
Female	37	41.2	89.8	(63.2-123.8)
Brain and Other Nervous System				
Male	21	18.5	113.6	(70.3-173.7)
Female	12	17.1	70.2	(36.2-122.6)
Breast				
Male	2	3	nc	(nc-nc)
Female	258	390	66.2	(58.3-74.7)
Cervix Uteri				
Female	17	13.7	123.8	(72.1-198.2)
Colon / Rectum				
Male	120	108.9	110.2	(91.4-131.8)
Female	142	130	109.2	(92-128.8)
Esophagus				
Male	26	25.4	102.3	(66.8-149.9)
Female	6	8.3	72.1	(26.3-156.9)
Hodgkin Lymphoma				
Male	12	8	149.5	(77.2-261.2)
Female	5	7.2	69.7	(22.5-162.6)
Kidney & Renal Pelvis				
Male	44	49.7	88.5	(64.3-118.8)
Female	30	32.5	92.4	(62.4-132)
Larynx				
Male	25	13.8	181.4	(117.3-267.7)
Female	9	4.7	192.8	(88-366.1)
Leukemia				
Male	35	38	92.2	(64.2-128.2)
Female	46	31.9	144.3	(105.7-192.5)
Liver and Intrahepatic Bile Ducts				
Male	29	29	100	(66.9-143.6)
Female	11	11.6	94.6	(47.2-169.3)
Lung and Bronchus				
Male	250	175.6	142.4	(125.3-161.2)
Female	199	203.9	97.6	(84.5-112.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	42	62.3	67.4	(48.6-91.1)
Female	24	54.7	43.9	(28.1-65.3)
Multiple Myeloma				
Male	16	17.2	92.8	(53-150.7)
Female	12	16.2	74.1	(38.2-129.4)
Non-Hodgkin Lymphoma				
Male	50	55.2	90.5	(67.2-119.4)
Female	58	51.9	111.8	(84.9-144.5)
Oral Cavity & Pharynx				
Male	48	39.7	120.8	(89-160.1)
Female	11	20	55.1	(27.5-98.6)
Ovary				
Female	28	36.5	76.7	(51-110.9)
Pancreas				
Male	33	31.9	103.6	(71.3-145.5)
Female	43	40.3	106.7	(77.2-143.8)
Prostate				
Male	296	346.2	85.5	(76-95.8)
Stomach				
Male	43	22.9	187.7	(135.8-252.8)
Female	27	16.2	166.6	(109.8-242.4)
Testis				
Male	18	13.4	134.5	(79.7-212.6)
Thyroid				
Male	20	21.9	91.2	(55.7-140.9)
Female	81	71.5	113.3	(90-140.8)
Uteri Corpus and Uterus, NOS				
Female	101	88.2	114.6	(93.3-139.2)
All Sites / Types				
Male	1344	1279.3	105.1	(99.5-110.8)
Female	1297	1405.3	92.3	(87.3-97.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	62	57.4	108.1	(82.8-138.5)
Female	14	20.3	68.9	(37.6-115.5)
Brain and Other Nervous System				
Male	14	8.7	161.1	(88-270.3)
Female	10	7.6	131.8	(63.1-242.4)
Breast				
Male	3	1.7	nc	(nc-nc)
Female	206	189.2	108.9	(94.5-124.8)
Cervix Uteri				
Female	5	5.8	85.7	(27.6-200)
Colon / Rectum				
Male	54	60.5	89.2	(67-116.4)
Female	51	61.9	82.4	(61.3-108.3)
Esophagus				
Male	14	14.4	97	(53-162.8)
Female	7	4.2	168.1	(67.3-346.3)
Hodgkin Lymphoma				
Male	4	3	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	22	26.4	83.3	(52.2-126.1)
Female	12	16	75.1	(38.8-131.3)
Larynx				
Male	8	7.8	103.1	(44.4-203.1)
Female	3	2.4	nc	(nc-nc)
Leukemia				
Male	20	20.1	99.4	(60.7-153.4)
Female	12	14.5	82.9	(42.8-144.8)
Liver and Intrahepatic Bile Ducts				
Male	18	15.8	114.1	(67.6-180.3)
Female	3	5.7	nc	(nc-nc)
Lung and Bronchus				
Male	77	102.8	74.9	(59.1-93.7)
Female	104	104.4	99.7	(81.4-120.7)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	29	33.6	86.3	(57.8-123.9)
Female	29	24.6	117.8	(78.9-169.2)
Multiple Myeloma				
Male	9	9.8	91.8	(41.9-174.3)
Female	7	8.1	86.8	(34.8-178.8)
Non-Hodgkin Lymphoma				
Male	31	29.5	105	(71.3-149)
Female	27	25	107.9	(71.1-157)
Oral Cavity & Pharynx				
Male	29	20.9	139.1	(93.1-199.7)
Female	7	9.7	72.4	(29-149.3)
Ovary				
Female	28	17.6	159.1	(105.7-230)
Pancreas				
Male	18	18.4	98	(58.1-155)
Female	19	19.7	96.4	(58-150.5)
Prostate				
Male	227	196.4	115.6	(101-131.6)
Stomach				
Male	13	12.9	100.5	(53.5-171.9)
Female	4	7.7	nc	(nc-nc)
Testis				
Male	3	3.9	nc	(nc-nc)
Thyroid				
Male	11	10.1	108.7	(54.2-194.5)
Female	15	29.2	51.4	(28.8-84.8)
Uteri Corpus and Uterus, NOS				
Female	42	44.5	94.3	(67.9-127.4)
All Sites / Types				
Male	720	709.5	101.5	(94.2-109.2)
Female	667	676.3	98.6	(91.3-106.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	31	38.6	80.4	(54.6-114.1)
Female	10	15.2	65.6	(31.4-120.6)
Brain and Other Nervous System				
Male	8	7.9	101.7	(43.8-200.4)
Female	9	6.8	131.6	(60.1-249.9)
Breast				
Male	2	1.2	nc	(nc-nc)
Female	131	152.3	86	(71.9-102)
Cervix Uteri				
Female	9	5.6	161.4	(73.6-306.4)
Colon / Rectum				
Male	30	43.6	68.8	(46.4-98.2)
Female	41	48.5	84.5	(60.7-114.7)
Esophagus				
Male	12	10.2	117.6	(60.7-205.4)
Female	2	3.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	6	3.6	165.6	(60.5-360.5)
Female	0	3.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	21	20.5	102.5	(63.4-156.7)
Female	12	12.5	96.4	(49.7-168.3)
Larynx				
Male	1	5.6	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)
Leukemia				
Male	14	15.4	90.6	(49.5-152.1)
Female	9	12.3	73	(33.3-138.6)
Liver and Intrahepatic Bile Ducts				
Male	9	11.9	75.4	(34.4-143.2)
Female	4	4.4	nc	(nc-nc)
Lung and Bronchus				
Male	88	69.6	126.4	(101.4-155.7)
Female	96	76	126.3	(102.3-154.3)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	17	25.3	67.1	(39.1-107.5)
Female	16	21.5	74.3	(42.4-120.6)
Multiple Myeloma				
Male	14	6.9	202.3	(110.5-339.5)
Female	8	6	132.4	(57-260.9)
Non-Hodgkin Lymphoma				
Male	27	22.5	119.9	(79-174.5)
Female	26	19.7	132.2	(86.3-193.7)
Oral Cavity & Pharynx				
Male	22	16.5	133.7	(83.8-202.4)
Female	9	7.7	117.6	(53.6-223.2)
Ovary				
Female	13	14.1	91.9	(48.9-157.2)
Pancreas				
Male	10	12.6	79.3	(38-145.9)
Female	10	14.8	67.4	(32.2-123.9)
Prostate				
Male	114	140	81.4	(67.2-97.8)
Stomach				
Male	9	9.1	98.7	(45-187.4)
Female	7	6	116.2	(46.5-239.4)
Testis				
Male	4	6.1	nc	(nc-nc)
Thyroid				
Male	2	9.4	nc	(nc-nc)
Female	17	29.6	57.4	(33.4-91.8)
Uteri Corpus and Uterus, NOS				
Female	45	34.3	131.3	(95.7-175.6)
All Sites / Types				
Male	475	516.8	91.9	(83.8-100.6)
Female	517	539.9	95.8	(87.7-104.4)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	3	1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Brain and Other Nervous System				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Breast				
Male	0	0	nc	(nc-nc)
Female	2	3	nc	(nc-nc)
Cervix Uteri				
Female	0	0.1	nc	(nc-nc)
Colon / Rectum				
Male	1	1.1	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Esophagus				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Hodgkin Lymphoma				
Male	0	0.1	nc	(nc-nc)
Female	0	0	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	0	0.5	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)
Larynx				
Male	0	0.2	nc	(nc-nc)
Female	0	0	nc	(nc-nc)
Leukemia				
Male	0	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	0	0.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Lung and Bronchus				
Male	1	1.8	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	0	0.6	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)
Multiple Myeloma				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	1	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)
Oral Cavity & Pharynx				
Male	1	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Ovary				
Female	0	0.3	nc	(nc-nc)
Pancreas				
Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)
Prostate				
Male	3	4	nc	(nc-nc)
Stomach				
Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)
Testis				
Male	0	0.1	nc	(nc-nc)
Thyroid				
Male	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)
Uteri Corpus and Uterus, NOS				
Female	1	0.7	nc	(nc-nc)
All Sites / Types				
Male	11	13.4	81.8	(40.8-146.4)
Female	9	10	90.5	(41.3-171.7)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	16	17	93.9	(53.7-152.6)
Female	5	6	82.8	(26.7-193.3)
Brain and Other Nervous System				
Male	5	3.6	140.3	(45.2-327.4)
Female	3	2.9	nc	(nc-nc)
Breast				
Male	1	0.5	nc	(nc-nc)
Female	75	69.8	107.4	(84.5-134.7)
Cervix Uteri				
Female	2	2.6	nc	(nc-nc)
Colon / Rectum				
Male	18	19.9	90.3	(53.5-142.7)
Female	22	19.1	115.1	(72.1-174.2)
Esophagus				
Male	3	4.8	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)
Hodgkin Lymphoma				
Male	1	1.5	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	8	9.9	81.1	(34.9-159.8)
Female	6	5.4	110.3	(40.3-240)
Larynx				
Male	0	2.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)
Leukemia				
Male	6	6.8	88.4	(32.3-192.5)
Female	6	4.9	123.1	(45-268)
Liver and Intrahepatic Bile Ducts				
Male	3	5.8	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)
Lung and Bronchus				
Male	31	31.9	97.1	(66-137.8)
Female	33	32.2	102.5	(70.5-143.9)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	19	11.7	163	(98.1-254.6)
Female	12	9.2	130.2	(67.2-227.5)
Multiple Myeloma				
Male	1	3.2	nc	(nc-nc)
Female	1	2.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	13	10.2	127.8	(68-218.5)
Female	8	8.1	98.2	(42.3-193.5)
Oral Cavity & Pharynx				
Male	7	8.1	86.9	(34.8-179.1)
Female	3	3.3	nc	(nc-nc)
Ovary				
Female	9	6.2	145.2	(66.3-275.7)
Pancreas				
Male	6	5.7	105	(38.3-228.5)
Female	6	5.8	104	(38-226.3)
Prostate				
Male	76	68.9	110.3	(86.9-138)
Stomach				
Male	6	4.1	144.7	(52.8-314.9)
Female	2	2.3	nc	(nc-nc)
Testis				
Male	3	2.3	nc	(nc-nc)
Thyroid				
Male	5	4.5	112.1	(36.1-261.5)
Female	17	13.4	126.8	(73.8-203)
Uteri Corpus and Uterus, NOS				
Female	21	16	131.2	(81.2-200.6)
All Sites / Types				
Male	248	240.6	103.1	(90.6-116.7)
Female	256	232.3	110.2	(97.1-124.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	52	68.1	76.4	(57-100.1)
Female	28	25.9	108	(71.8-156.1)
Brain and Other Nervous System				
Male	15	13.7	109.5	(61.3-180.7)
Female	5	11.6	43.1	(13.9-100.6)
Breast				
Male	1	2.1	nc	(nc-nc)
Female	276	270.3	102.1	(90.4-114.9)
Cervix Uteri				
Female	12	10.2	118.1	(61-206.4)
Colon / Rectum				
Male	81	77.7	104.2	(82.8-129.5)
Female	95	82.9	114.6	(92.7-140.1)
Esophagus				
Male	18	18.2	98.7	(58.5-156.1)
Female	7	5.2	134.5	(53.9-277.2)
Hodgkin Lymphoma				
Male	4	6.1	nc	(nc-nc)
Female	5	5.1	98.5	(31.8-230)
Kidney & Renal Pelvis				
Male	38	36.8	103.3	(73.1-141.8)
Female	18	21.7	83.1	(49.2-131.3)
Larynx				
Male	5	10	50.1	(16.2-117)
Female	3	3.1	nc	(nc-nc)
Leukemia				
Male	28	27	103.8	(68.9-150)
Female	29	20.8	139.1	(93.2-199.8)
Liver and Intrahepatic Bile Ducts				
Male	19	21.3	89.2	(53.7-139.4)
Female	8	7.5	106.2	(45.7-209.2)
Lung and Bronchus				
Male	107	123.3	86.8	(71.1-104.9)
Female	135	130.1	103.8	(87-122.8)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	38	45.2	84.1	(59.5-115.4)
Female	30	37.7	79.5	(53.6-113.5)
Multiple Myeloma				
Male	15	12.3	122	(68.2-201.2)
Female	11	10.4	106.2	(53-190.1)
Non-Hodgkin Lymphoma				
Male	40	39.8	100.5	(71.8-136.8)
Female	32	33.9	94.5	(64.6-133.4)
Oral Cavity & Pharynx				
Male	24	29.6	81	(51.9-120.5)
Female	9	13.4	67.3	(30.7-127.8)
Ovary				
Female	23	24.8	92.9	(58.8-139.4)
Pancreas				
Male	27	22.4	120.5	(79.4-175.4)
Female	24	25.2	95.3	(61.1-141.8)
Prostate				
Male	239	251.8	94.9	(83.3-107.7)
Stomach				
Male	17	16.3	104.6	(60.9-167.5)
Female	14	10.2	136.7	(74.7-229.4)
Testis				
Male	8	10.7	75.1	(32.3-148)
Thyroid				
Male	17	16.9	100.4	(58.5-160.8)
Female	49	53.4	91.8	(67.9-121.4)
Uteri Corpus and Uterus, NOS				
Female	64	61	105	(80.9-134.1)
All Sites / Types				
Male	862	920	93.7	(87.5-100.2)
Female	994	940	105.7	(99.3-112.5)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2007-2011

	Obs	Exp	SIR	95% CI
Bladder, Urinary				
Male	29	23.8	122.1	(81.7-175.3)
Female	9	8.5	105.4	(48.1-200.1)
Brain and Other Nervous System				
Male	4	5.9	nc	(nc-nc)
Female	5	4.7	106.6	(34.4-248.8)
Breast				
Male	0	0.8	nc	(nc-nc)
Female	114	109	104.6	(86.3-125.6)
Cervix Uteri				
Female	3	4.4	nc	(nc-nc)
Colon / Rectum				
Male	32	29.3	109.4	(74.8-154.4)
Female	36	28.2	127.8	(89.5-177)
Esophagus				
Male	8	6.8	116.9	(50.3-230.3)
Female	3	1.7	nc	(nc-nc)
Hodgkin Lymphoma				
Male	2	2.6	nc	(nc-nc)
Female	4	2	nc	(nc-nc)
Kidney & Renal Pelvis				
Male	16	14.9	107.7	(61.5-175)
Female	14	8.2	170.8	(93.3-286.6)
Larynx				
Male	8	3.8	209.1	(90-412.1)
Female	0	1.2	nc	(nc-nc)
Leukemia				
Male	12	10.4	115.8	(59.8-202.3)
Female	4	7.7	nc	(nc-nc)
Liver and Intrahepatic Bile Ducts				
Male	9	8.5	106.3	(48.5-201.7)
Female	2	2.7	nc	(nc-nc)
Lung and Bronchus				
Male	34	44.2	76.9	(53.3-107.5)
Female	42	45.4	92.6	(66.7-125.2)

	Obs	Exp	SIR	95% CI
Melanoma of Skin				
Male	14	17.3	80.9	(44.2-135.7)
Female	14	14.8	94.9	(51.8-159.2)
Multiple Myeloma				
Male	9	4.6	196.5	(89.7-373.1)
Female	2	3.5	nc	(nc-nc)
Non-Hodgkin Lymphoma				
Male	9	15.3	58.7	(26.8-111.4)
Female	14	12.1	115.4	(63.1-193.7)
Oral Cavity & Pharynx				
Male	12	12.2	98.6	(50.9-172.3)
Female	3	5	nc	(nc-nc)
Ovary				
Female	6	9.5	63.3	(23.1-137.8)
Pancreas				
Male	10	8.1	123.9	(59.3-227.8)
Female	7	8.2	85.8	(34.4-176.8)
Prostate				
Male	119	96.4	123.4	(102.3-147.7)
Stomach				
Male	7	6	117.3	(47-241.7)
Female	3	3.4	nc	(nc-nc)
Testis				
Male	3	4.5	nc	(nc-nc)
Thyroid				
Male	8	7.3	109.8	(47.3-216.4)
Female	26	23.5	110.9	(72.4-162.4)
Uteri Corpus and Uterus, NOS				
Female	26	24	108.4	(70.8-158.8)
All Sites / Types				
Male	372	348.3	106.8	(96.2-118.2)
Female	368	353.8	104	(93.7-115.2)

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;